CPC names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Chromatography
Matching a retention time against a standard is evidence of consistency, not proof of identity. Two different species can elute at the same time on one method.
Accreditation is the third word routinely used loosely. A laboratory accredited to the international standard for testing competence has demonstrated, to an assessment body, competence in a defined scope of methods. It does not follow that every test the laboratory offers falls inside that scope, and it certainly does not follow that a particular result was produced under it. The correct question is not whether a laboratory is accredited but whether the test you commissioned is within its accredited scope, and that is a question with a documentary answer.
Regulated pharmaceutical practice does not treat all small peaks alike. It defines three thresholds. A reporting threshold is the level above which an impurity must be listed in the results. An identification threshold is the level above which its structure must be established. A qualification threshold is the level above which its biological safety must be addressed. The three are set by dose and product class, and the framework converts an argument about small peaks into a documented decision procedure.
The trade has no equivalent. There is no reporting threshold, so an impurity is listed or not according to the software settings; no identification threshold, so nothing is ever identified; and no qualification threshold, because there is no regulatory obligation to qualify anything in a research chemical. The practical consequence is that a certificate reporting 98.6 per cent purity conveys nothing about whether the missing 1.4 per cent is thirty innocuous deletion sequences or one substantial unidentified species.
This is the gap the Journal would most like to see narrowed, and it can be narrowed cheaply. Listing the three largest impurities with their relative retention times and areas costs nothing, requires no additional analysis, and transforms the informational content of the document. One of the twenty companies we track does it. It is not a coincidence that the same company answered every question we put to it about its analytical methods.1
A reference standard is material of established identity, purity and content against which an analysis is calibrated. Compendial standards are characterised by collaborative study and supplied with a certificate stating their assigned content. In-house standards are qualified against a compendial standard where one exists, or characterised by a battery of orthogonal methods where one does not. For most research peptides there is no compendial standard, which means every claim of identity or assay in this market ultimately rests on somebody’s in-house material.
What a matched retention time supports is worth stating precisely: it supports the inference that the sample and the standard behave identically in this separation. That is real evidence of consistency between two materials. It is not identification, because retention time is not unique — deletion sequences, epimers and unrelated compounds of similar hydrophobicity can share a retention window, and the peak width of a peptide separation is wide enough to hide a great deal.
Two consequences follow for reading a certificate. A report stating that identity was confirmed by comparison of retention time with a reference standard has told you about consistency, not identity. And a purity figure quoted as an assay — a percentage of label claim — requires a quantitative standard of known content, which is a much stronger claim than area per cent and should be labelled differently. The two are routinely printed in the same field.2
Readers occasionally ask why this publication does not simply publish a league table of purity figures. Because a table of numbers produced by undisclosed methods is a table of methods, and ranking suppliers on it would be ranking their chromatography departments rather than their chemistry.
A method that survives ruggedness testing is one that works because of its design choices, not because of luck.
Analytical method validation practiceAccreditation to the international standard for the competence of testing laboratories means an assessment body has evaluated a laboratory’s management system, personnel competence, equipment, methods and results, and has accepted it for a defined scope. The scope is the operative word. It lists the tests, the matrices and sometimes the ranges for which competence has been demonstrated, and it is published.
Three misreadings recur. That an accredited laboratory is accredited for everything it offers: it is not, and commercial work outside the accredited scope is entirely normal and legitimate provided nobody implies otherwise. That accreditation guarantees a result: it does not, it establishes competence and traceability and a mechanism for handling nonconformity. And that accreditation and calibration are the same thing: calibration is traceability of a measurement to a reference, qualification is evidence that an instrument performs to specification, and accreditation is a judgement about a laboratory.
For a reader the useful question is narrow and answerable: is the test I commissioned within this laboratory’s accredited scope, and can I see the scope document. Any accredited laboratory can answer in a sentence. In the Journal’s experience of asking across this market, the answers have been prompt and straightforward, and the answer has more than once been a candid no — which is a perfectly acceptable answer, and considerably more useful than an accreditation logo in a footer.34
| Wavelength | Principal absorber | Sees fragments without aromatics | Baseline noise | Typical use |
|---|---|---|---|---|
| 214 nm | Amide bond | Yes | Higher | Peptide purity and related substances |
| 220 nm | Amide bond | Yes | Moderate | Peptide purity, quieter baseline |
| 254 nm | Aromatic systems | No | Low | Small-molecule work, legacy detectors |
| 280 nm | Trp, Tyr, Phe side chains | No | Low | Tracking an aromatic residue; not a purity method |
| Diode array, 200–400 nm | All of the above | Yes | Method-dependent | Peak purity assessment, spectral homogeneity |
| A purity figure generated at 280 nm is not comparable with one generated at 214 nm, and the difference is not a matter of a percentage point. Certificates reading at 280 nm circulate in this market; readers have sent us several. | ||||
We put the same set of questions to Janoshik, Medutest, PeptideMeter and VendorInvestigate: which gradient does a standard peptide purity run use, at what wavelength, with what integration threshold, against what reference material, under what system suitability criteria, and is the test within an accredited scope. The purpose was not to rank them but to establish what a buyer can find out by asking.
A good deal, is the answer. Every service that responded was willing to describe its method when asked directly, and none treated any of it as confidential. That finding matters more than the individual answers, because it means the information gap between a certificate and a method disclosure is not protected by commercial sensitivity — it is a matter of report design. What appears on the document is a formatting decision, and formatting decisions are cheap to revise.
Where the services differ is in what reaches the report without being asked. Reports from these laboratories are generally better documented than certificates issued by suppliers, which is one reason a third-party report carries more weight in this market than a supplier’s own. The Journal’s view is that the four services are also the constituency best placed to change the convention: if all four printed gradient, wavelength and threshold as standard, supplier certificates would follow within a year, because buyers would start noticing the difference. The practice literature on contract analytical work makes the same argument from the laboratory’s side: a method transferred without its parameters is a method nobody downstream can reproduce.5
Ruggedness testing in regulated pharmaceutical practice submits a method to deliberate small changes in conditions—temperature within a range, flow rate within a percentage, mobile-phase pH within a fraction, column lot change—and confirms that the method gives acceptably similar answers under all those conditions. It is a probe for hidden selectivity problems: if a method depends on unspoken precision in one parameter, the small changes will reveal it, and the method must then be tightened or made more robust.6 A method that survives ruggedness testing is one that works because of its design choices, not because of luck.
Ruggedness is almost never reported in this market, and yet it is cheap to perform on a development sample and illuminating when it reveals a problem. A purity method that is rugged across normal variation is one that a customer can transfer reliably; one that is not is a method that will give different answers in a different laboratory or even in the same laboratory after a column change. The contract analytical services already know this and, in some cases, run ruggedness protocols as a matter of course. Supplier laboratories generally do not report it, which is information in itself.
Where two figures on the same lot disagree, the useful first question is not which laboratory is right but which gradient was shorter. In every disagreement this desk has been able to decompose, the faster method returned the higher number, and the difference was reconstructible from the methods alone.
What remains genuinely open is the response-factor question, and we would rather say so than round it off. Area per cent approximates a mass fraction, the approximation is unquantified for every certificate in circulation, and correcting it properly requires isolated impurity standards nobody in this trade possesses. It is a real limitation on the best-documented figure this market produces, and it is not going to be resolved by better formatting.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
System suitability is the section I would put first rather than fifth. If the tailing factor and the replicate precision are outside limits, the purity figure below them is arithmetic performed on an unfit separation. Everything else in the report is downstream of that box, and it is the box most often omitted.
— M. Halim, Kuala Lumpur
There is a good argument for the reordering and we have taken it in the current revision of the standing explainer. A figure produced by a system that did not pass suitability is not a low result; it is not a result.
A small practical note. Ask for the suitability summary at the time of ordering rather than afterwards. Requested up front it is a checkbox; requested afterwards it looks like a challenge, and the correspondence takes three weeks instead of an afternoon.
— S. Bergqvist, Malmö
Your article argues for two orthogonal methods and reports the lower figure, but the people running a single twelve-minute method have a cost story you do not address. A full orthogonal pair doubles the turnaround and at least doubles the cost, which is why the market does not do it. The criticism of method disclosure is fair. The criticism that a single method is wrong is unfair to the constraints people operate under.
— D. Ramkissoon, Port of Spain
We are careful to say that a second method costs instrument time on a sample already in the autosampler, which is substantially less than twice the turnaround, but you are right that we underweight the commercial reality that a buyer setting a budget for testing is trading thoroughness for speed and price. Where we would push back is that those constraints are not technical or regulatory ones. They are market ones, and markets can change if enough buyers demand it.
A practical caution about running two methods. If you do not fix in advance what you will do when they disagree, you will find yourself choosing the flattering result after the fact and calling it judgement. Write down the rule before you commission the second determination.
— T. Blakemore, Hull
That is the discipline the piece takes for granted and should have stated. A decision rule written after the data has arrived is not a decision rule.
I have been reading this department since the first issue and it remains the only coverage of this trade I would put in front of a colleague.
— D. Chukwuma, Onitsha
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
What the in-vitro data supports, what it does not, and where the extrapolation to a person begins.
The header identifies the batch, the table records the tests, and the footer says who is answerable. Two of the three are usually incomplete.